Newsletter Tool

Today’s Big News

Apr 10, 2024

AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech

Bristol Myers-backed TORL secures $158M to march army of ADCs through clinic

AACR: To bring CAR-T to solid tumors, Poseida thinks we need to boost conditioning therapy

AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class

AACR: Mural debuts preclinical data for potential cytokine therapy pipeline additions

Amid corporate restructuring, Novartis plots 680 layoffs in development group

Thank you to Quest Diagnostics for sponsoring our editorial feature: AACR 2024

Featured

AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech

By Annalee Armstrong

A session at the American Association for Cancer Research annual meeting asked a key question: Are cancer vaccines ready for prime time? If you ask Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, the answer is a quick yes.

Bristol Myers-backed TORL secures $158M to march army of ADCs through clinic

By James Waldron

For companies exploring the antibody-drug conjugate arena, the interest from Big Pharma and big-pocketed investors appears to be as strong as ever.

AACR: To bring CAR-T to solid tumors, Poseida thinks we need to boost conditioning therapy

By Annalee Armstrong

Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of the puzzle with a new analysis presented at the American Association for Cancer Research.

AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class

By Annalee Armstrong

IL-2 medicines have shown the ability to kill tumors. Synthekine hopes to do this without the associated toxicities with a new IL-2 alpha/beta molecule.

AACR: Mural debuts preclinical data for potential cytokine therapy pipeline additions

By Helen Floersh

It’s been a busy five months since Mural Oncology landed its first big check after spinning out of Alkermes. Now, the company has released its first data on IL-18 and IL-12-targeting cytokine therapies that overcome longtime limitations for the field.

Amid corporate restructuring, Novartis plots 680 layoffs in development group

By Fraiser Kansteiner

Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational unit.

Alcanza acquires Innovation Medical Research Center location outside Miami

By Helen Floersh

Orlando-based clinical trials facilities network Alcanza Clinical Research has purchased a Florida site of Innovation Medical Research Center, its ninth acquisition since 2021.

As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake

By Angus Liu

At an FDA advisory committee meeting this Friday, two teams will present their studies examining the utility of minimal residue disease (MRD) as a potentially approvable endpoint in multiple myeloma. For this report, Fierce Pharma spoke with experts to learn about what's at stake, including the need to bring new treatments to patients earlier.

Fierce podcasts

Don’t miss an episode

The unrecognized threat of PAD

This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.

Seen and unseen: A closer look at barriers to inclusive care for trans men

'The Top Line': The top money raisers in biotech

Resources

eBook

Discover the future of mAb manufacturing

Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

Sponsored by: PPD®️ Laboratory Services